Last reviewed · How we verify

Uritos (IMIDAFENACIN)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 30/100

Uritos (generic name: IMIDAFENACIN) is a drug. It is currently FDA-approved for Bladder muscle dysfunction - overactive.

Uritos is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat overactive bladder, as indicated by clinical trials comparing its efficacy and safety to Urotol.

At a glance

Generic nameIMIDAFENACIN
TargetMuscarinic acetylcholine receptor M3
ModalitySmall molecule
Therapeutic areaUrology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Uritos

What is Uritos?

Uritos (IMIDAFENACIN) is a Small molecule drug, indicated for Bladder muscle dysfunction - overactive.

What is Uritos used for?

Uritos is indicated for Bladder muscle dysfunction - overactive.

What is the generic name of Uritos?

IMIDAFENACIN is the generic (nonproprietary) name of Uritos.

What development phase is Uritos in?

Uritos is FDA-approved (marketed).

What does Uritos target?

Uritos targets Muscarinic acetylcholine receptor M3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing